When cells are faced with conditions that damage the genetic blueprint of a cell (genotoxic stress), a choice between two major fates-life or death-must be made. As this decision is crucial, many regulatory mechanisms are in place to ensure the correct choice. The survival response is coupled to the induction of cellcycle arrest at checkpoints in different phases of the cell cycle. This permits DNA repair, which may be associated with the induction of genes promoting cell survival. In contrast, induction of distinct molecular events that culminate in activation of common cell-death pathways mediates cell death. A key question is how the cell regulates the checks and balances of these complex processes to ensure that healthy cells survive and genetically damaged cells that might lead to tumor formation do not. Some proteins can act as switches for these opposing cell fates. In this issue of Cell, Janssens et al. (2005) reveal a new switch in this fundamental decision-making process called PIDD (p53-induced protein with a death domain).
PIDD was originally identified as a gene that depended on p53 for its expression (Lin et al., 2000) . PIDD induces cell-cycle arrest and apoptosis when overexpressed in p53-deficient human cell lines, suggesting that PIDD may act downstream of p53 in promoting cell death induced by p53. Later, Tinel and Tschopp (2004) demonstrated that PIDD associates with RAIDD (RIP-associated ICH-1/ECD3-homologous protein with a death domain) and procaspase-2 to form a so-called "PIDDosome" that initiates apoptosis through a mitochondrial-dependent pathway (Tinel and Tschopp, 2004) . In their new study, Janssens et al. (2005) demonstrate that PIDD is important for activating an antiapoptotic pathway involving the transcription factor NF-κB in response to genotoxic stress.
When a cell is exposed to a DNAdamaging agent, the transcription factor NF-κB often turns on cell-survival genes. Previous studies identified multiple important upstream events in In response to genotoxic stress, the PIDD protein promotes apoptosis downstream of the tumor-suppressor protein p53. In this issue of Cell, Janssens et al. (2005) demonstrate that, in response to such stress, PIDD forms a nuclear complex that enhances sumoylation of NEMO. This modification is important for the activation of the antiapoptotic transcription factor NF-κB. PIDD forms a cytoplasmic "PIDDosome" composed of PIDD, RAIDD, and procaspase-2 to promote apoptosis through a mitochondrial death pathway in response to genotoxic stimuli. PIDD also forms a nuclear PIDDosome containing RIP1 and NEMO (also known as IKKγ) to promote SUMO-1 attachment on NEMO in response to genotoxic and perhaps other stresses. Nuclear RIP1 is also posttranslationally modified in an undefined manner (denoted by "?"). Following NEMO sumoylation, ATM, also activated by genotoxic agents through the induction of DNA damage, such as double-strand breaks, stimulates a subsequent NEMO modification cascade. These modifications cause NEMO translocation from the nucleus to the cytoplasm, where it causes the displacement of IκB (which gets degraded). This leads to the release of free NF-κB in the cytoplasm, which then enters the nucleus to induce prosurvival gene transcription.
PIDD: A Switch Hitter
NF-κB signal transduction pathways induced by several DNA-damaging agents. An important molecule downstream of DNA damage is ATM (ataxia telangiectasia mutated), a nuclear kinase that is required for NF-κB activation in response to many DNA-damaging agents, particularly those that induce DNA double-strand breaks (Huang et al., 2003; Li et al., 2001) . ATM is also important for the regulation of cell-cycle checkpoints, DNA repair, and apoptosis in the face of doublestrand breaks (Bakkenist and Kastan, 2004) . Another pivotal upstream event is a posttranslational modification of NEMO (NF-κB essential modulator) by SUMO-1 (small ubiquitin-like modifier 1) (Huang et al., 2003) . This modification is independent of ATM. Sumoylation of NEMO induces a subsequent cascade of events, most notably phosphorylation and ubiquitination of NEMO itself (both modifications are ATM dependent). These modifications cause the translocation of NEMO from the nucleus into the cytoplasm, where it causes the release of NF-κB from an inhibitory complex in the cytoplasm (Huang et al., 2003) . This in turn allows NF-κB to enter the nucleus and turn on genes important for cell survival (see Figure 1) . In an in vitro assembly assay using cell extracts derived from cultured cells stably overexpressing PIDD, Janssens, Tinel, and colleagues (2005) found that PIDD formed a separate complex that contained RIP1 (receptor-interacting protein 1) and NEMO and lacked RAIDD and procaspase-2. Both RIP1 and NEMO are critical players in the signaling pathways that lead to activation of the transcription factor NF-κB by several DNA-damaging agents (Huang et al., 2003; Hur et al., 2003) . Thus, the authors decided to investigate whether PIDD also modulated this activation pathway. Indeed, PIDD overexpression promoted phosphorylation of IκBα (inhibitor of NF-κB α). This phosphorylation event is essential for the dissociation of IκBα from NF-κB and the translocation of NF-κB into the nucleus. Therefore, PIDD overexpression promotes NF-κB-dependent transcription in response to genotoxic agents, such as etoposide. Silencing of endogenous PIDD by small interfering RNAs (siRNAs) reduced NF-κB activation by etoposide, thus corroborating the overexpression results. This is an exciting turn of events, given that NF-κB activation is linked to tumor formation and the resistance of human cancers to chemotherapy and radiation treatment (Karin and Greten, 2005) . Understanding how PIDD regulates this pathway may provide insights into the development of future drugs against cancer. Janssens et al. (2005) found that PIDD intersected the NF-κB signaling pathway at the step of NEMO sumoylation. PIDD overexpression was associated with increased detection of sumoylated NEMO and augmentation of subsequent NEMO phosphorylation and ubiquitination events. These modifications were diminished when PIDD levels in cells were reduced (using specific siRNAs to target PIDD transcripts for degradation). Furthermore, both the association of PIDD with NEMO and NEMO modifications were absent in human leukemic cells lacking RIP1. This indicates that RIP1 is necessary for these events to take place. Coimmunoprecipitation experiments demonstrated that PIDD associates with RIP1 and unmodified NEMO in vitro; however, in vivo, PIDD selectively associates with sumoylated NEMO and RIP1. Surprisingly, unmodified NEMO was not found in the PIDD complex in extracts isolated from cells treated with DNA-damaging agents. Moreover, PIDD undergoes nuclear translocation in response to genotoxic stress, whereas NEMO and RIP1 remain in both the cytoplasm and nucleus before and after DNA damage. Given that sumoylated NEMO was only found in the nucleus following DNA damage, the PIDD-RIP1-sumoylated NEMO complex appears to reside exclusively in the nucleus (see Figure 1) .
The introduction of PIDD into the NEMO sumoylation pathway by Janssens et al. (2005) raises a number of interesting questions. First, how does PIDD increase the amount of sumoylated NEMO in the nucleus? As PIDD does not seem to contain motifs present in known SUMO ligases, it does not appear to be a direct SUMO ligase for NEMO. Thus, PIDD may enhance the interaction between NEMO and a SUMO ligase to promote the sumoylation reaction. This analysis awaits the identification of the SUMO ligase for NEMO. Alternatively, the absence of unmodified NEMO in the PIDD complex in vivo suggests that PIDD may associate selectively with the SUMO-1-modified form of NEMO in the nucleus and may protect it from attack by a protease that mediates SUMO removal (the SUMO protease for NEMO also remains to be identified). This also touches upon the question regarding the mechanism of assembly of the PIDD-RIP1-sumoylated NEMO complex in vivo. Is the complex formed in the cytoplasm and then imported into the nucleus, or do all of the components enter into the nucleus separately and then form a complex? In either case, the possibility that PIDD prevents desumoylation of SUMO-modified NEMO is of particular interest, given that the steady-state levels of many sumoylated proteins (with the exception of Ran-GAP1, the first SUMO target identified) are much lower than expected (Hay, 2005) . In this context, it will be interesting to determine whether the capacity of PIDD to increase sumoylation is limited only to NEMO or whether there are multiple PIDDosomes containing different sumoylated proteins that participate in different molecular pathways.
The question also arises whether DNA damage per se is necessary to induce the assembly of the nuclear PIDDosome or whether some other stress (such as oxidative stress that is also induced by the genotoxic agents) is causing formation of PIDDosomes. Given that PIDD promotes cell death by forming a separate PIDDosome with RAIDD and procaspase-2, presumably in the cytoplasm (see Figure  1 ), how does PIDD know which type of PIDDosome to associate with under different conditions? Cell-free assembly assays indicate that the PIDD-RIP1-NEMO complex forms earlier than the PIDD-RAIDD-procaspase-2 complex in vitro. However, elucidation of the regulatory mechanisms involved in the assembly of these distinct com-In one of the great pioneering experiments in the field of developmental biology, Hans Spemann divided amphibian embryos at the two-cell stage into separate halves by ligation with a human baby's hair and then monitored the ability of the two halves to generate a complete amphibian body plan (discussed in English in Spemann [1938] ). If the embryos were separated along the typical plane of cleavage, which separates the left and right sides of the embryo, two fully formed twins developed. Remarkably, however, if two-cell frog embryos were split perpendicular to the typical cleavage plane resulting in dorsal and ventral halves of the embryo, a very different result was observed. One of the cells developed into a relatively disorganized mass of tissue that Spemann called the bauchstück (belly piece) as it contained no dorsal structures (see Figure 1A) . Surprisingly, the other cell developed into a relatively well-proportioned embryo. Spemann's results showed that the amphibian embryo has the ability to compensate for the missing ventral half (called self-regulation). How this selfregulation works at a molecular level has been a mystery that has lasted for more than a hundred years. Since Spemann's original ligation experiment, a great deal has been learned about the mechanisms that pattern the early amphibian embryo. Soon after fertilization, a "dorsalizing activity" moves from the bottom of the embryo toward one side, which will become the future dorsal-anterior pole. By default, the opposite side will become the ventral-posterior pole (for simplicity, these will be referred to as the dorsal and ventral poles of the embryo). The dorsalizing activity locally stabilizes β-catenin, the Wnt intracellular signal transducer, which subsequently activates genes involved plexes in vivo may differ depending on the cellular setting. Another point that requires further investigation is where ATM fits into this pathway. Janssens et al. (2005) imply that ATM acts downstream of the PIDD-RIP1-NEMO PIDDosome; however, a previous study has shown that ATM is necessary for the association of RIP1 with NEMO (Hur et al., 2003) . Additionally, given that NF-κB acts primarily as an antiapoptotic factor but also can serve as a proapoptotic factor, depending on cellular conditions and the DNAdamaging agents used (Campbell et al., 2004) , the PIDD-RIP1-sumoylated NEMO complex may act as an inducer of apoptosis, depending on the cellular conditions. Answers to these questions may provide clues to how PIDD acts as a molecular switch to turn life and death pathways on and off in the face of genetic damage in different cellular environments.
